ANEXO 1. Metodología de búsqueda
A. Adquisición y búsqueda de la evidencia:
Beneficios clínicos y económicos de la rifaximina comparada con la neomicina en el
tratamiento del Síndrome de Intestino Irritable (IBS)
B. Estrategia y algoritmos de búsqueda:
1. Términos MeSH* (literatura anglosajona) y DeCS** (México y el Caribe,
Latinoamérica)
Términos MeSH y DeCS

Irritable Bowel Syndrome [MeSH]

Síndrome de Intestino Irritable (DeCS)

Irritable Bowel Syndrome/treatment [MeSH]

“pinaverium ”[Substance Name]

"tegaserod "[Substance Name]

"rifaximin "[Substance Name]

"Anti-Infective Agents"[Mesh]

Costs and Cost Analysis [MeSH]

Costos y Análisis de costo (DeCS)


Cost Benefit Analysis [MeSH]***
Small Intestinal Bacterial Overgrowth
2. Límites y operadores “booleanos”
 Estudios en humanos, idiomas (inglés, español, portugués,…),
adultos (>=19 años)
 Estudios clínicos y/o “Clinical Trials” y/o “Systematic Reviews” y/o
“Meta-analysis”
 “Booleanos”: “AND”, “OR” y “NOT”.
3. Estrategias de búsqueda
 Límites, búsqueda histórica y búsqueda avanzada
 Clinical queries: Clinical Study Category; systematic reviews
 Special queries: HSR Study Category, category economics (broad and
narrow search)
*Medical Subject Heading
**Descriptores en Ciencias de la Salud
***NOTA: el término MeSH “Cost Benefit Analysis”, está indizado en muchas bases
de datos (eg Medline-NLM) como un concepto que cubre todas las evaluaciones
económicas completas (ACE [análisis costo-efectividad, ACU [análisis costo-utilidad,
minimización de costos y el propio ACB [análisis costo-beneficio])
4. Bases de datos consultadas:
 National Library Medicine (PubMed-Medline)
 Cochrane Library Plus
Database of Systematic Reviews
 LILACS
 Artemisa
 Scielo
5. Máscaras de búsqueda:
 PubMed
 OvidSP (Wolters Kluwer)
 EBSCO y EBSCO-HOST
 Springerlink
 MedicLatina
C. Bibliografía obtenida:
1. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a
technical review for practice guideline development. Gastroenterology 1997;
112:2120–37.
2. Hasler WL, Owyang C. Irritable bowel syndrome. In: Yamada T. ed. Textbook
of Gastroenterology, Vol. 2. Philadelphia: J.B. Lippincott Company,
1995:1832.
3. Quigley EM. Disturbances of motility and visceral hypersensitivity in irritable
bowel syndrome: biological markers or epiphenomenon. Gastroenterol Clin
North Am 2005; 34: 221–33.
4. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade
inflammatory bowel disease? Gastroenterol Clin North Am 2005; 34: 235–45.
5. Chang L. Brain responses to visceral and somatic stimuli in irritable bowel
syndrome: a central nervous system disorder? Gastroenterol Clin North Am
2005; 34: 271–9.
6. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after
bacterial gastroenteritis: cohort study. Brit Med J 1999; 318: 565–6.
7. Marshall JK, Thabane M, et al, for the WEL Investigators. Incidence and
epidemiology of irritable bowel syndrome after a large waterborne outbreak of
bacterial dysentery. Gastroenterology 2006; 131: 445–50.
8. Chaudhary NA, Truelove SC. The irritable colon syndrome. Quart J Med 1962;
123: 307–22
9. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial
overgrowth reduces symptoms of irritable bowel syndrome. Am J
Gastroenterol. 2000;95:3503-6.
10. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing
correlates with symptom improvement in irritable bowel syndrome: a
doubleblind, randomized, placebo-controlled study. Am J Gastroenterol.
2003;98:412-9.
11. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibañez A, Coderch J, et al.
Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis
outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98104.
12. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of
enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious
IBS. Gastroenterology. 2003;125:1651-9.
13. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, et al.
Analysis of the fecal microbiota of irritable bowel syndrome patients and
healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373-82.
14. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus
and bifidobacterium in irritable bowel syndrome: symptom responses and
relationship to cytokine profiles. Gastroenterology. 2005;128:541-51.
15. Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for
small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305-11.
16. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding
irritable bowel syndrome. JAMA. 2004;292:852-8.
17. Drossman DA. The functional gastrointestinal disorders and the Rome III
process. In: Drossman DA, Corazziari E, Delvaux M, Spiller R, Talley NJ,
Thompson WG, et al., eds. Rome III: The Functional Gastrointestinal
Disorders.3rd ed. McLean, VA: Degnon Associates; 2006:1-30.
18. Drossman DA. The functional gastrointestinal disorders and the Rome III
process. Gastroenterology. 2006;130:1377-90.
19. Longstreth GF, Thompson G, Chey WD, Houghton LA, Mearin F, Spiller RC.
Functional Bowel Disorders. Gastroenterology 2006;130:1480-1491.
20. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the
management of irritable bowel syndrome in North America. Am J
Gastroenterol 2002; 11 (Suppl. ): S7–26.
21. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome:
what works and does not work. Gastroenterol Clin North Am 2005; 34:319–
35.
22. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of
alosetron in women with severe diarrheapredominant irritable bowel
syndrome. Am J Gastroenterol 2004; 99:2195–203.
23. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza R. Rifaximin versus
chlortetracycline in the short-term treatment of small intestinal bacterial
overgrowth. Aliment Pharmacol Ther 2000; 14: 551-556.
24. Pimentel M, Park S, Kane SV. Rifaximin, a nonabsorbable, gut-selective
antibiotic, improves the symptoms of irritable bowel syndrome: a randomized,
double-blind, placebo-controlled study.Ann Intern Med 2006; 145: 557–63.
25. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo
response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;
3:237–47.
26. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo
controlled, randomised study to evaluate the efficacy, safety, and tolerability
of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671–6.
27. Thompson CA. Novartis suspends tegaserod sales at FDA’s request. Am J
Health Syst Pharm 2007 64: 1020.
28. Secretaria de Salud – COFEPRIS. Comunicado a los profesionales de la salud.
Tegaserod (Zelmac). 18 de Junio de 2007
29. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle
relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol
Ther 2001; 15: 355-361.
30. Levy C, Charbonnier A, Cachin M. Pinaverium bromide and functional colonic
disease (double-blind study). Sem Hop Ther 1977; 53: 372–4.
31. Delmont J. The value of adding an antispasmodic musculotropic agent in the
treatment of painful constipation in functional colopathies with bran. Doubleblind study. Med Chir Dig 1981; 10: 365–70
32. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for
the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther
2005; 22: 31–5
33. Di Stefano M, Strocchi A, Malservisi S, et al. Nonabsorbable antibiotics for
managing intestinal gas production and gas-related symptoms. Aliment
Pharmacol Ther 2000; 14:1001–8.
34. King TS, Ekua M, Hunter JO. Abnormal colonic fermentation in irritable bowel
syndrome. Lancet. 1998; 352:1187-1189
35. Sen S, Dear KL, King TS, Hunter JO. Evaluation of hydrogen excretion after
lactulose administration as a screening test for causes of irritable bowel
syndrome. Eur J Gastroenterol Hepatol. 2002;14:753-756.
36. Choi YK, Johlin FCJ, Summers RW, Jackson M, Rao SS. Fructose intolerance:
an under-recognized problem. Am J Gastroenterol. 2003;98:1348-1353
37. Abrahamsson H. Gastrointestinal motility in patients with the irritable bowel
syndrome. Scand J Gastroenterol Suppl. 1987;130:21-26.
38. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the
irritable colon syndrome. Gut. 1973;14:125-132.
39. Silverman DHS, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA.
Regional cerebral activity in normal and pathologic perception of visceral pain.
Gastroenterology. 1997;112:64-72.
40. Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel
syndrome correlate with specific autonomic nervous system abnormalities.
Gastroenterology. 1994;106:945-950.
41. Chadwick V, Chen W, Shu D, et al. Activation of the mucosal immune system
in irritable bowel syndrome. Gastroenterology. 2002;122:1778-1783
42. Nayak A, Karnad D, Abraham P, Mistry FP. Metronidazole relieves symptoms
in irritable bowel syndrome: the confusion with so-called “chronic amebiasis.”
Indian J Gastroenterol. 1997;16:137-139.
43. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for
the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther
2005; 22: 31–5.
44. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized
double-blind placebo-controlled trial of rifaximin in patients with abdominal
bloating and flatulence. Am J Gastroenterol 2006; 101: 326–33.
45. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves
constipation-predominant irritable bowel syndrome in a fashion that is
dependent on the presence of methane gas: subanalysis of a double-blind
randomized controlled study. Dig Dis Sci 2006; 51:1297–301.
46. Esposito I, De Leone A, Di Gregorio G, Giaquinto S, et al. Breath test for
differential diagnosis between small intestinal bacterial overgrowth and
irritable bowel disease: An observation on non-absorbable antibiotics. World J
Gastroenterol 2007 December 7; 13(45): 6016-6021
47. Thabane M, Kottachchi T, Marshall K. Systematic review and meta-analysis:
the incidence and prognosis of post-infectious irritable bowel syndrome.
Aliment Pharmacol Ther; 2007:26, 535–544
48. Lesbros-Pantoflickova d, Michetti p, Fried M, et al. Meta-analysis: the
treatment of irritable bowel syndrome. Aliment Pharmacol 2004; 20: 1253–
1269.
49. Delmont J. The value of adding an antispasmodic musculotropic agent in the
treatment of painful constipation in functional colopathies with bran. Doubleblind study. Med Chir Dig 1981; 10: 365–70
50. Levy C, Charbonnier A, Cachin M. Pinaverium bromide and functional colonic
disease (double-blind study). Sem Hop Ther 1977; 53: 372–4.
51. Tougas G, Snape WJ , Otten MH, et al. Long-term safety of tegaserod in
patients with constipation predominant irritable bowel syndrome. Aliment
Pharmacol Ther 2002; 16: 1701–1708